1. Progression-free survival was significantly greater in the durvalumab plus bevacizumab group compared to placebo. 2. Common treatment-related adverse events ...
1. Cadonilimab plus chemotherapy significantly improved progression-free survival in patients with persistent, recurrent, or metastatic cervical cancer. 2. Common grade ...
1. The Atezolizumab group demonstrated significantly greater progression-free and overall survival among patients with metastatic, persistent, or recurrent cervical cancer. ...
1. The Atezolizumab group demonstrated significantly greater progression-free and overall survival among patients with metastatic, persistent, or recurrent cervical cancer. ...
Click here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
1. In patients with diabetic macular edema, aflibercept monotherapy showed no difference in vision improvement compared to step therapy of ...
Click to read this study in The Lancet Oncology.
1. In a large, international cohort of infants with retinopathy of prematurity (ROP) treated with intravitreal anti-VEGF injections, the rate ...
1. Atezolizumab plus capecitabine + bevacizumab performed marginally better with regards to progression free survival in patients with metastatic colorectal ...
1. Cancer biosimilar treatment trials have clinical outcomes that do not differ statistically from reference biologic products 2. The design ...
